×

SteadyMed Announces Pricing of Initial Public Offering

SAN RAMON, Calif., March 20, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd., a specialty pharmaceutical company, today announced the pricing of its initial public offering of 4,700,000 ordinary shares at a price to the public of $8.50 per share. SteadyMed's ordinary shares are expected to begin trading on The NASDAQ Global Market under the symbol "STDY" on March 20, 2015. The offering is expected to close on March 25, 2015, subject to customary closing conditions. All of the ordinary shares are being offered by SteadyMed. In addition, SteadyMed has granted the underwriters a 30-day option to purchase up to an additional 705,000 ordinary shares.

Wells Fargo Securities, LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, or by telephone at (800) 326‐5897, or by email at cmclientsupport@wellsfargo.com; or from RBC Capital Markets, Attn: Prospectus Department, 200 Vesey Street 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by emailing equityprospectus@rbccm.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 19, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead candidate is Trevyent, a development stage drug product that utilizes SteadyMed's PatchPump technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel.

CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com Robert H. Uhl Managing Director Westwicke Partners 858-356-5932 robert.uhl@westwicke.comSource: SteadyMed Therapeutics